Resveratrol in human cancer chemoprevention - choosing the 'right' dose

Molecular Nutrition and Food Research

Volumn 56, Issue 1, 2012, Pages 7-13

  Scott, Edwina ^a   Steward, William P ^a   Gescher, Andreas J ^a   Brown, Karen ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Cancer chemoprevention; Dose; Pharmacodynamics; Pharmacokinetics; Resveratrol

Indexed keywords

ANTINEOPLASTIC AGENT; RESVERATROL; STILBENE DERIVATIVE;

ANIMAL; DOSE RESPONSE; DRUG SCREENING; HUMAN; NEOPLASM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; STILBENES;

RODENTIA;

EID: 84855334376     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201100400     Document Type: Review

References (35)

1. Boffetta, P., Couto, E., Wichmann, J., Ferrari, P. et al., Fruit and vegetable intake and overall cancer risk in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J. Natl. Cancer Inst. 2010, 102, 529-537.
2. Willett, W. C., Fruits, vegetables, and cancer prevention: turmoil in the produce section. J. Natl. Cancer Inst. 2010, 102, 510-511.
3. Hung, H. C., Joshipura, K. J., Jiang, R., Hu, F. B. et al., Fruit and vegetable intake and risk of major disease. J. Natl. Cancer Inst. 2004, 96, 1577-1584.
4. Jang, M., Cai, L., Udeani, G. O., Slowing, K. V. et al., Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275, 218-220.
5. Baur, J. A., Sinclair, D. A., Therapeutic potential of resveratrol: the in vivo evidence. Nature Rev. Drug Discov. 2006, 5, 493-506.
6. Vang, O., Ahmad, N., Baile, C. A., Baur, J. A. et al., What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLOS One 2011, 6, e19881.
7. Kristal, A. R., Lippman, S. M., Nutritional prevention of cancer: new directions for an increasingly complex challenge. J. Natl. Cancer Inst. 2009, 101, 363-365.
8. Athar, M., Back, J. H., Tang, X., Kim, K. H. et al., Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol. 2007, 224, 274-283.
9. Calabrese, E. J., Mattson, M. P., Calabrese, V., Resveratrol commonly displays hormesis: occurrence and biomedical significance. Hum. Exp. Toxicol. 2010, 29, 980-1015.
10. Kaiser, J., Sipping from a poisoned chalice. Science 2003, 302, 376-379.
11. Gu, J., Wang, C. Q., Fan, H. H., Ding, H. Y. et al., Effects of resveratrol on endothelial progenitor cells and their contributions to re-endothelialization in intima-injured rats. J. Cardiovasc. Pharmacol. 2006, 47, 711-721.
12. Tessitore, L., Davit, A., Sarotto, I., Caderni, G., Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. Carcinogenesis 2000, 21, 1619-1622.
13. Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H., Skipper, H. E., Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother. Rep. 1966, 50, 219-245.
14. Reagan-Shaw, S., Nihal, M., Ahmad, N., Dose translation from animal to human studies revisited. FASEB J. 2008, 22, 659-661.
15. Sengottuvelan, M., Viswanathan, P., Nalini, N., Chemopreventive effect of trans-resveratrol - a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1, 2-dimethylhydrazine-induced colon carcinogenesis. Carcinogenesis 2006, 27, 1038-1046.
16. Schneider, Y., Duranton, B., Gosse, F., Schleiffer, R. et al., Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis. Nutr. Cancer 2001, 39, 102-107.
17. Min+ mouse and cyclooxygenase-2 in human-derived colon cancer cells. Int. J. Cancer 2005, 115, 194-201.
18. Harper, C. E., Patel, B. B., Wang, J., Arabshahi, A. et al., Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis 2007, 28, 1946-1953.
19. Goldberg, D. M., Yan, J., Soleas, G. J., Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin. Biochem. 2003, 36, 79-87.
20. La Porte, C., Voduc, N., Zhang, G. J., Seguin, I. et al., Steady-state pharmacokinetics and tolerability of trans-resveratrol 2000mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin. Pharmacokinet. 2010, 49, 449-454.
21. Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E., Walle, U. K., High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 2004, 32, 1377-1382.
22. Boocock, D. J., Faust, G. E. S., Patel, K. R., Schinas, A. M. et al., Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 1246-1252.
23. Brown, V., Patel, K., Viskaduraki, M., Crowell, J. et al., Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics and effect on the insulin-like growth factor axis. Cancer Res. 2010, 70, 9003-9011.
24. Chow, H. H. S., Garland, L. L., Hsu, C. H., Vining, D. R. et al., Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev. Res. 2010, 3, 1168-1175.
25. Patel, K. R., Brown, V. A., Jones, D. J. L., Britton, R. G. et al., Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 2010, 70, 7392-7399.
26. Urpi-Sarda, M., Jauregui, O., Lamuela-Raventos, R. M., Jaeger, W. et al., Uptake of diet resveratrol into the human low-density lipoprotein. Identification and quantification of resveratrol metabolites by liquid chromatography coupled with tandem mass spectrometry. Anal. Chem. 2005, 77, 3149-3155.
27. Vitaglione, P., Sforza, S., Galaverna, G., Ghidini, C. et al., Bioavailability of trans-resveratrol from red wine in humans. Mol. Nutr. Food Res. 2005, 49, 495-504.
28. Burkon, A., Somoza, V., Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides - two novel resveratrol metabolites in human plasma. Mol. Nutr. Food Res. 2008, 52, 549-557.
29. Ortuño, J., Covas, M. I., Farre, M., Pujadas, M. et al., Matrix effects on the bioavailability of resveratrol in humans. Food Chem. 2010, 120, 1123-1130.
30. Zamora-Ros, R., Urpi-Sarda, M., Lamuela-Raventos, R. M., Estruch, R. et al., Diagnostic performance of urinary resveratrol metabolites as a biomarker of moderate wine consumption. Clin. Chem. 2006, 52, 1373-1380.
31. Gescher, A. J., Steward, W. P., Relationship between mechanisms, bioavailability and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol. Biomarkers Prev. 2003, 12, 953-957.
32. Hoshino, J., Park, E. J., Kondratyuk, T. P., Marler, L. et al., Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J. Med. Chem. 2010, 53, 5033-5043.
33. Calamini, B., Ratia, K., Malkowski, M. G., Cuendet, M. et al., Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem. J. 2010, 429, 273-282.
34. Lamikanra, O., Grimm, C. C., Rodin, J. B., Inyang, I. D., Hydroxylated stilbenes in selected American wines. J. Agric. Food Chem. 1996, 44, 1111-1115.
35. Brown, K., Tompkins, E. M., White, I. N., Applications of accelerator mass spectrometry for pharmacological and toxicological research. Mass Spectrom. Rev. 2005, 25, 127-145.